682 related articles for article (PubMed ID: 17392160)
1. Activation of caspase-6 in aging and mild cognitive impairment.
Albrecht S; Bourdeau M; Bennett D; Mufson EJ; Bhattacharjee M; LeBlanc AC
Am J Pathol; 2007 Apr; 170(4):1200-9. PubMed ID: 17392160
[TBL] [Abstract][Full Text] [Related]
2. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease.
Guo H; Albrecht S; Bourdeau M; Petzke T; Bergeron C; LeBlanc AC
Am J Pathol; 2004 Aug; 165(2):523-31. PubMed ID: 15277226
[TBL] [Abstract][Full Text] [Related]
3. Memory performance is related to amyloid and tau pathology in the hippocampus.
Reitz C; Honig L; Vonsattel JP; Tang MX; Mayeux R
J Neurol Neurosurg Psychiatry; 2009 Jul; 80(7):715-21. PubMed ID: 19258354
[TBL] [Abstract][Full Text] [Related]
4. Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain.
Rohn TT; Rissman RA; Davis MC; Kim YE; Cotman CW; Head E
Neurobiol Dis; 2002 Nov; 11(2):341-54. PubMed ID: 12505426
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease.
Mizukami K; Akatsu H; Abrahamson EE; Mi Z; Ikonomovic MD
Neuropathology; 2016 Apr; 36(2):135-45. PubMed ID: 26293308
[TBL] [Abstract][Full Text] [Related]
6. Caspase-6 activation in familial alzheimer disease brains carrying amyloid precursor protein or presenilin i or presenilin II mutations.
Albrecht S; Bogdanovic N; Ghetti B; Winblad B; LeBlanc AC
J Neuropathol Exp Neurol; 2009 Dec; 68(12):1282-93. PubMed ID: 19915487
[TBL] [Abstract][Full Text] [Related]
7. Visual association pathology in preclinical Alzheimer disease.
McKee AC; Au R; Cabral HJ; Kowall NW; Seshadri S; Kubilus CA; Drake J; Wolf PA
J Neuropathol Exp Neurol; 2006 Jun; 65(6):621-30. PubMed ID: 16783172
[TBL] [Abstract][Full Text] [Related]
8. Caspase-6 as a novel early target in the treatment of Alzheimer's disease.
LeBlanc AC
Eur J Neurosci; 2013 Jun; 37(12):2005-18. PubMed ID: 23773070
[TBL] [Abstract][Full Text] [Related]
9. Activation of caspase-8 in the Alzheimer's disease brain.
Rohn TT; Head E; Nesse WH; Cotman CW; Cribbs DH
Neurobiol Dis; 2001 Dec; 8(6):1006-16. PubMed ID: 11741396
[TBL] [Abstract][Full Text] [Related]
10. Progression of Alzheimer-related neuritic plaque pathology in the entorhinal region, perirhinal cortex and hippocampal formation.
Yilmazer-Hanke DM; Hanke J
Dement Geriatr Cogn Disord; 1999; 10(2):70-6. PubMed ID: 10026378
[TBL] [Abstract][Full Text] [Related]
11. Brainstem tau pathology in Alzheimer's disease is characterized by increase of three repeat tau and independent of amyloid β.
Uematsu M; Nakamura A; Ebashi M; Hirokawa K; Takahashi R; Uchihara T
Acta Neuropathol Commun; 2018 Jan; 6(1):1. PubMed ID: 29298724
[TBL] [Abstract][Full Text] [Related]
12. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
[TBL] [Abstract][Full Text] [Related]
13. Olfactory tau pathology in Alzheimer disease and mild cognitive impairment.
Attems J; Jellinger KA
Clin Neuropathol; 2006; 25(6):265-71. PubMed ID: 17140156
[TBL] [Abstract][Full Text] [Related]
14. Increased Caspase-6 activity in the human anterior olfactory nuclei of the olfactory bulb is associated with cognitive impairment.
Foveau B; Albrecht S; Bennett DA; Correa JA; LeBlanc AC
Acta Neuropathol Commun; 2016 Dec; 4(1):127. PubMed ID: 27931265
[TBL] [Abstract][Full Text] [Related]
15. Histopathological and immunohistochemical comparison of the brain of human patients with Alzheimer's disease and the brain of aged dogs with cognitive dysfunction.
Yu CH; Song GS; Yhee JY; Kim JH; Im KS; Nho WG; Lee JH; Sur JH
J Comp Pathol; 2011 Jul; 145(1):45-58. PubMed ID: 21256508
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of C-terminally truncated tau protein associated with vulnerability of the perforant pathway in early stages of neurofibrillary pathology in Alzheimer's disease.
García-Sierra F; Wischik CM; Harrington CR; Luna-Muñoz J; Mena R
J Chem Neuroanat; 2001 Jul; 22(1-2):65-77. PubMed ID: 11470555
[TBL] [Abstract][Full Text] [Related]
17. Tau load is associated with apolipoprotein E genotype and the amount of amyloid beta protein, Abeta40, in sporadic and familial Alzheimer's disease.
Thaker U; McDonagh AM; Iwatsubo T; Lendon CL; Pickering-Brown SM; Mann DM
Neuropathol Appl Neurobiol; 2003 Feb; 29(1):35-44. PubMed ID: 12581338
[TBL] [Abstract][Full Text] [Related]
18. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease.
Streit WJ; Braak H; Xue QS; Bechmann I
Acta Neuropathol; 2009 Oct; 118(4):475-85. PubMed ID: 19513731
[TBL] [Abstract][Full Text] [Related]
19. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease.
Cummings BJ; Pike CJ; Shankle R; Cotman CW
Neurobiol Aging; 1996; 17(6):921-33. PubMed ID: 9363804
[TBL] [Abstract][Full Text] [Related]
20. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.
Sasaki N; Fukatsu R; Tsuzuki K; Hayashi Y; Yoshida T; Fujii N; Koike T; Wakayama I; Yanagihara R; Garruto R; Amano N; Makita Z
Am J Pathol; 1998 Oct; 153(4):1149-55. PubMed ID: 9777946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
